TrialThe lancet. Diabetes & endocrinology2020

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.

Nicklas J Johansen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.